Both printed sources and scientific and practical events pay considerable attention to the identification, diagnosis and treatment of the consequences and complications of coronavirus infection (COVID‑19). Among the whole range of conferences devoted to this issue, events with a non-standard format are especially interesting, for example, the webinar “Neuro-COVID Trilogy”, which takes place in the format of a discussion club. The first part of the webinar covered the pathophysiology of post-COVID complications, the second – the evidence base for their treatment, and the third – the practical nuances of the use of drugs. The highlight of the discussion is that clinical neurologists and a clinical pharmacologist present their views on the issues discussed in parallel. The moderator of the event was Tatyana Ivanovna Nasonova, Doctor of Medical Sciences (P.L. A. Bogomolets (Kyiv, Department of Clinical Pharmacology) and Candidate of Medical Sciences Viktor Oleksandrovich Kholin (Institute of Gerontology named after D. F. Chebotarev of the National Academy of Medical Sciences of Ukraine, Kyiv).
- COVID‑19 and PCS are heterogeneous pathological conditions involving a wide range of neurological and psychopathological manifestations. In particular, asthenia, cognitive disorders and anxiety are typical.
- In case of neurological diseases, including neurological manifestations and complications of COVID-19, it is advisable to use L-carnitine (Metacartin, World Medicine, UK) as a drug with a polyvalent metabolic (antihypoxic, anabolic, antioxidant) effect.
- Neurological disorders associated with COVID-19 require the repair of neuronal membranes and their supporting cells. For this purpose, citicoline (Ronocyte, World Medicine, UK) can be used, which is incorporated into membranes, improving their structure and function, as well as improving neuroplasticity.